Animal Study Reveals CardioPhase Reduces Myocardial Damage Induced by Isopropylarterenol

Du Xiao-yang, First Hospital of Xi’an Jiaotong University, Xi’an 710061, China

Researchers in China have identified heart disease (cardiopathy) as a leading cause of mortality, accounting for over twelve million deaths per year.

In the past few years our team has succeeded in developing an improved version of a traditional Chinese compound possessing the ability to enhance heart metabolism, protect myocardial tissues from injury and promote recovery of cardiac performance following sever cardiac injury. Initial animal studies of this new compound, CardioPhase (CP) reveal that the formula is effective at protecting from myocardial necrosis induced by isopropylarterenol. Specifically the results of previous animal studies revealed significant improvements in electrocardiogram [ECG] readings, myocardial enzymes, and blood serum concentrations of vitamin E.

Pharmacodynamics Experiment
We tested the effects of CardioPhase on neonate rat myocardial cells damaged by Isoprenaline (isopropylarterenol), a beta-agonist that induces tachycardia, cardiac arrhythmias, palpitations and hypotension. The results of our tests indicate that CardioPhase reduces pulse rate, enhances pulse strength and regulates (normalizes) pulse rhythm. Also noted were improvements in myocardial cell membrane structure and mitochondrial function.

Acute Hemodyanimcs Experiment
We conducted a further study designed to determine the acute hemodynamic effects of CardioPhase on rats with congestive heart failure (CHF). Tests were performed on two groups - a CardioPhase-treated group and a control group receiving only water. Both groups possessed nearly the same state of congestive heart failure, induced by ischemic or dilated cardiomyopathy. Test results showed that the mean pulmonary arterial pressure (MPAP) and pulmonary wedge pressure (PWP) of the subjects were significantly reduced and positive cardiac index scores elevated in the CardioPhase-treated group. These effects were not observed in the control group, suggesting that the effects of CardioPhase in cases of chronic heart failure CHF are due to its ability to markedly improve cardiac pump function.

Pathologic evaluations revealed that the total area, quality and extent of myocardial necrosis in the CardioPhase-treated group were significantly lower than in control rats, indicating that CardioPhase was effectively alleviating myocardial damage caused by induced anoxic and ischemic damage to cardiocytes. These results showed that CardioPhase can improve ECG of rats with myocardia obstructive ischemic injury.

Further evaluations of the protective benefits of CardioPhase after induced myocardial necrosis showed that the formula works to decrease phosphocreatine kinase (CPK), lactate dehydrogenase (LDH), glutamic-oxalacetic transaminase (GOT) and hydroxybutyrate dehydrogenase (HBDH), indicating improved myocardial nutrition metabolism. CardioPhase also reduced both free fatty acid (FFA) concentrations and TBA values of lipid peroxide in rat plasma, indicating that the formula enhances the body’s ability to scavenge free radicals to alleviate myocardial necrosis.

Pharmacology Experiment
Acute-term toxicity tests showed that the median lethal dose (LD50) of CardioPhase was more than 220 g/kg. According to the classification standards of acute toxicity of chemicals, CardioPhase is nontoxic.

Long-term toxicity tests showed that rat weight, liver and kidney function, hemogram and main organs were without obvious damage in three months after three months feeding of CardioPhase by stomach feeding in the small, medium and large dose groups.